Realistic illustration of long COVID patients improving from fatigue and brain fog via NAD+ supplement trial at Massachusetts General Hospital.
Picha iliyoundwa na AI

NAD+ supplement shows early promise for long COVID fatigue and brain fog

Imeripotiwa na AI Picha iliyoundwa na AI Imethibitishwa ukweli

A randomized controlled trial at Massachusetts General Hospital tested high-dose nicotinamide riboside, a vitamin B3 derivative, to boost NAD+ levels in people with long COVID. Although between-group differences were limited, participants who took the supplement for at least 10 weeks reported improvements in fatigue, sleep, mood, and some executive function measures compared with their own baseline, suggesting potential benefits for some individuals despite mixed overall results.

Tovuti hii inatumia vidakuzi

Tunatumia vidakuzi kwa uchambuzi ili kuboresha tovuti yetu. Soma sera ya faragha yetu kwa maelezo zaidi.
Kataa